Skip To Main Content
J. Weisner on Muck Rack

J. Weisner

As seen in: Medium, Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with J.

Contact J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST

|
By T. Schulz, A. Teuber, L. Ebel, A. George, J. Weisner, M. P. Muller, S. Wilhelm, S. Sievers, S. Bauer, M. Beerbaum, A. Scrima, H. Jantzen, T. Mühlenberg, F. Garcia-Fossa, N. Berner, D. Rauh
| Nature Verified
Abstract Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Current tyrosine kinase inhibitors (TKIs) targeting oncogenic KIT and PDGFRA have improved patient outcomes, yet off-target toxicities and drug resistance mutations remain major clinical challenges.
Open in Who Shared Issue with article?

peeks on new pictures by J. Weisner

|
By J. Weisner
| Medium
Hey there 👋 I have great news: There are new pictures on their way to my Unsplash. These are my favourite ones from the already uploaded ones. In the first one I’ve again tried some lightpainting. As you might guess, it didn’t went as planned, but thats life. And for it is my hobby, my aim is to grow with every picture. I just want to encourage you to try. Because sometimes you are gonna have luck.
Open in Who Shared Issue with article?

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA - Nature Communications

|
By T. Schulz, S. Bauer, A. Teuber, R. Gontla, J. Niggenaber, J. Weisner, J. Lategahn, S. Sievers
| Nature Verified
Abstract Avapritinib is the only potent and selective inhibitor approved for the treatment of D842V-mutant gastrointestinal stromal tumors (GIST), the most common primary mutation of the platelet-derived growth factor receptor α (PDGFRA). The approval was based on the NAVIGATOR trial, which revealed overall response rates of more than 90%.
Open in Who Shared Issue with article?
See all 3 articles